Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (GMAIS)
A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window
Sponsor: California Pacific Medical Center Research Institute
This PHASE2 trial investigates Stroke and is currently completed. California Pacific Medical Center Research Institute leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Sep 2018 — Sep 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- California Pacific Medical Center Research Institute
- Columbia University
- Genervon Biopharmaceuticals, LLC
- Hoag Memorial Hospital Presbyterian
- Huntington Hospital
- Sarasota Memorial Hospital
- University Hospital Erlangen
- University of California, Los Angeles
- University of Louisville
For direct contact, visit the study record on ClinicalTrials.gov .